Abstract
Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 1263-1266 |
| Number of pages | 4 |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy |
| Volume | 21 |
| Issue number | 8 |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
Keywords
- breast cancer
- CPT-11
- irinotecan
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Cite this
Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan). / Doihara, Hiroyoshi; Takashima, S.; Yokoyama, N.
In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 21, No. 8, 1994, p. 1263-1266.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Four cases of recurrent breast cancer effectively treated by the new ntitumor agent, CPT-11 (irinotecan)
AU - Doihara, Hiroyoshi
AU - Takashima, S.
AU - Yokoyama, N.
PY - 1994
Y1 - 1994
N2 - Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.
AB - Four cases of recurrent breast cancer effectively treated by CPT-11 were reported. These cases had undergone previous chemotherapy including adriamycin. Nevertheless, they developed no tolerance to such therapies and displayed good responsitivity to CPT-11. Effects on metastatic lesions: One was bone and three were soft tissues was observed after the end of one course therapy. The response periods were over 210 days, 431 days, 175 days and 73 days. Thus, it was suggested that early response to drug was important clinically and was significant for enhancing the quality of life of patients. Major adverse reactions were leukopenia and gastrointestinal symptoms such as nausea, vomiting and diarrhea (Grade 2-3). However, these could be well managed by symptomatic treatment and dose modification. The results suggested that CPT-11 was an effective agent against advanced or recurrent breast cancer, and especially useful for patients who had developed a tolerance to previous therapies.
KW - breast cancer
KW - CPT-11
KW - irinotecan
UR - http://www.scopus.com/inward/record.url?scp=0028041276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028041276&partnerID=8YFLogxK
M3 - Article
C2 - 8031169
AN - SCOPUS:0028041276
VL - 21
SP - 1263
EP - 1266
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 8
ER -